Compare Invesco DB Oil Fund (DBO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Gilead Sciences, Inc. — how do they compare? Invesco DB Oil Fund trades at $21.06, while Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Invesco DB Oil Fund pays none, and Invesco DB Oil Fund is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| DBO | GILD | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $23.80 | $155.80 |
52-Week Low | $11.98 | $110.56 |
Market Cap | — | $168.35B |
Enterprise Value | — | $191.42B |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
